The long patent dispute between PharmaResearch and BMI Korea over the PDRN manufacturing method has finally come to an end, with the court ruling in favor of the original company, PharmaResearch.

The industry expects the trial win to bring momentum to the rise of PDRN-based pharmaceuticals and devices, such as ‘Rejuran’ and ‘Conjuran.’ If the company also wins the patent infringement trial that follows, PharmaResearch will also be able to hold the generics in check, solidifying its position as the original product.

◆ Managing Director Kiseok Kang, “Court recognized our original technology"

According to industry sources, the Patent Court of Korea ruled in favor